help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Published ahead of print on February 20, 2003, doi:10.1164/rccm.200208-905OC

Am. J. Respir. Crit. Care Med., Volume 167, Number 12, June 2003, 1687-1694

A more recent version of this article appeared on June 15, 2003
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200208-905OCv1
167/12/1687    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fujimoto, H.
Right arrow Articles by Taguchi, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fujimoto, H.
Right arrow Articles by Taguchi, O.

Submitted on August 25, 2002
Accepted on February 17, 2003

Thrombin-activatable fibrinolysis inhibitor and protein C inhibitor in interstitial lung disease

Hajime Fujimoto1, Esteban C Gabazza1*, Osamu Hataji1, Hisamichi Yuda1, Corina N D'Alessandro-Gabazza1, Mariko Nakano2, Omar E Franco3, Tatsuya Hayashi2, Koji Suzuki2, Yukihiko Adachi1, and Osamu Taguchi1

1 Respiratory Division of The Third Department of Internal Medicine, Mie University School of Medicine, Tsu, Mie, Japan, 2 Molecular Pathobiology, Mie University School of Medicine, Tsu, Mie, Japan, 3 Urology, Mie University School of Medicine, Tsu, Mie, Japan

* To whom correspondence should be addressed. E-mail: gabazza{at}clin.medic.mie-u.ac.jp.

Intraalveolar activation of the coagulation system due to reduced fibrinolytic function plays a critical role in the pathogenesis of interstitial lung disease. Recently, a new potent inhibitor of fibrinolysis, thrombin-activatable fibrinolysis inhibitor, has been isolated and characterized from human plasma. This study evaluated the levels of thrombin-activatable fibrinolysis inhibitor and protein C inhibitor, another suppressor of fibrinolysis, in the bronchoalveolar lavage fluid from patients with interstitial lung disease. There were 82 patients with interstitial lung disease and 8 normal subjects. The bronchoalveolar lavage fluid levels of thrombin-activatable fibrinolysis inhibitor and protein C inhibitor were significantly higher in all patients with interstitial lung disease than in normal subjects. Both inhibitors of fibrinolysis were significantly and inversely correlated with fibrinolytic activity in all patients. The levels of thrombin-activatable fibrinolysis inhibitor were significantly correlated with those of protein C inhibitor, thrombin-antithrombin complex and monocyte chemoattractant protein-1. Reverse transcriptase-polymerase chain reaction showed that alveolar macrophages isolated from patients with interstitial lung disease as well as immortalized lung epithelial cell lines express thrombin-activatable fibrinolysis inhibitor antigen. Overall, these findings suggest that thrombin-activatable fibrinolysis inhibitor and protein C inhibitor may play important roles in the mechanism of intraalveolar hypofibrinolysis associated with interstitial lung diseases.
Key words: lung fibrosis, plasmin, coagulation, activated protein C, metalloproteinases




This article has been cited by other articles:


Home page
 ERRHome page
R. C. Chambers
Abnormal wound healing responses in pulmonary fibrosis: focus on coagulation signalling
Eur. Respir. Rev., December 1, 2008; 17(109): 130 - 137.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J-F. Cordier
Cryptogenic organising pneumonia.
Eur. Respir. J., August 1, 2006; 28(2): 422 - 446.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
H. Fujimoto, E. C. Gabazza, O. Taguchi, Y. Nishii, H. Nakahara, N. E. Bruno, C. N. D'Alessandro-Gabazza, M. Kasper, Y. Yano, M. Nagashima, et al.
Thrombin-Activatable Fibrinolysis Inhibitor Deficiency Attenuates Bleomycin-Induced Lung Fibrosis
Am. J. Pathol., April 1, 2006; 168(4): 1086 - 1096.
[Abstract] [Full Text] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
O. Kaftan, O. S. Balcik, H. Cipil, G. Ozet, N. Bavbek, A. Kosar, and S. Dagdas
Plasma Levels of Thrombin-Activatable Fibrinolysis Inhibitor in Primary and Secondary Thrombocytosis
Clinical and Applied Thrombosis/Hemostasis, October 1, 2005; 11(4): 449 - 454.
[Abstract] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. Tobin
Tuberculosis, Lung Infections, Interstitial Lung Disease, Social Issues and Journalology in AJRCCM 2003
Am. J. Respir. Crit. Care Med., January 15, 2004; 169(2): 288 - 300.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. M. Strieter
To Clot or Not to Clot, That Is the Question in Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med., June 15, 2003; 167(12): 1589 - 1590.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2003 American Thoracic Society 		  SOTA, FL